Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SHR-3032 in Healthy Subjects
NCT06090799Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- Biological product
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in graft rejection comparing SHR-3032 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events/serious adverse events at Day 99, Pharmacokinetic parameter of SHR-3032: Cmax at Day 99 and 6 more. Started Nov 2023; status: completed.
02
Drugs
SHR-3032
03
Conditions
graft rejection
Beyond the preview
Go deeper on NCT06090799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06090799.